Literature DB >> 22072053

Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.

José das Neves1, Johan Michiels, Kevin K Ariën, Guido Vanham, Mansoor Amiji, Maria Fernanda Bahia, Bruno Sarmento.   

Abstract

PURPOSE: To assess the intracellular delivery, antiretroviral activity and cytotoxicity of poly(ε-caprolactone) (PCL) nanoparticles containing the antiretroviral drug dapivirine.
METHODS: Dapivirine-loaded nanoparticles with different surface properties were produced using three surface modifiers: poloxamer 338 NF (PEO), sodium lauryl sulfate (SLS) and cetyl trimethylammonium bromide (CTAB). The ability of nanoparticles to promote intracellular drug delivery was assessed in different cell types relevant for vaginal HIV transmission/microbicide development. Also, antiretroviral activity of nanoparticles was determined in different cell models, as well as their cytotoxicity.
RESULTS: Dapivirine-loaded nanoparticles were readily taken up by different cells, with particular kinetics depending on the cell type and nanoparticles, resulting in enhanced intracellular drug delivery in phagocytic cells. Different nanoparticles showed similar or improved antiviral activity compared to free drug. There was a correlation between increased antiviral activity and increased intracellular drug delivery, particularly when cell models were submitted to a single initial short-course treatment. PEO-PCL and SLS-PCL nanoparticles consistently showed higher selectivity index values than free drug, contrasting with high cytotoxicity of CTAB-PCL.
CONCLUSIONS: These results provide evidence on the potential of PCL nanoparticles to affect in vitro toxicity and activity of dapivirine, depending on surface engineering. Thus, this formulation approach may be a promising strategy for the development of next generation microbicides.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22072053     DOI: 10.1007/s11095-011-0622-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  50 in total

1.  In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.

Authors:  Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity.

Authors:  Yonehiro Kanemura; Hideki Mori; Satoshi Kobayashi; Omedul Islam; Eri Kodama; Atsuyo Yamamoto; Youko Nakanishi; Norio Arita; Mami Yamasaki; Hideyuki Okano; Masayuki Hara; Jun Miyake
Journal:  J Neurosci Res       Date:  2002-09-15       Impact factor: 4.164

Review 3.  Gels as vaginal drug delivery systems.

Authors:  J das Neves; M F Bahia
Journal:  Int J Pharm       Date:  2006-03-17       Impact factor: 5.875

4.  In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection.

Authors:  Katty Terrazas-Aranda; Yven Van Herrewege; Paul J Lewi; Jens Van Roey; Guido Vanham
Journal:  Antivir Chem Chemother       Date:  2007

Review 5.  The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.

Authors:  Myron S Cohen; Nick Hellmann; Jay A Levy; Kevin DeCock; Joep Lange
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

Review 6.  Mucoadhesive nanosystems for vaginal microbicide development: friend or foe?

Authors:  José das Neves; Mansoor Amiji; Bruno Sarmento
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-04-19

7.  Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide.

Authors:  A David Woolfson; R Karl Malcolm; Ryan J Morrow; Clare F Toner; Stephen D McCullagh
Journal:  Int J Pharm       Date:  2006-06-23       Impact factor: 5.875

8.  Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS.

Authors:  Lipa K Shah; Mansoor M Amiji
Journal:  Pharm Res       Date:  2006-09-13       Impact factor: 4.200

Review 9.  Microbicides and HIV prevention: lessons from the past, looking to the future.

Authors:  Georgina C Morris; Charles J N Lacey
Journal:  Curr Opin Infect Dis       Date:  2010-02       Impact factor: 4.915

10.  Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission.

Authors:  Yven Van Herrewege; Lieve Penne; Chris Vereecken; Katrien Fransen; Guido van der Groen; Luc Kestens; Jan Balzarini; Guido Vanham
Journal:  AIDS Res Hum Retroviruses       Date:  2002-10-10       Impact factor: 2.205

View more
  19 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

Review 2.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

3.  Biodistribution and pharmacokinetics of dapivirine-loaded nanoparticles after vaginal delivery in mice.

Authors:  José das Neves; Francisca Araújo; Fernanda Andrade; Mansoor Amiji; Maria Fernanda Bahia; Bruno Sarmento
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

4.  Spray drying tenofovir loaded mucoadhesive and pH-sensitive microspheres intended for HIV prevention.

Authors:  Tao Zhang; Chi Zhang; Vivek Agrahari; James B Murowchick; Nathan A Oyler; Bi-Botti C Youan
Journal:  Antiviral Res       Date:  2012-12-26       Impact factor: 5.970

5.  Hydrophobic-core PEGylated graft copolymer-stabilized nanoparticles composed of insoluble non-nucleoside reverse transcriptase inhibitors exhibit strong anti-HIV activity.

Authors:  Anita Leporati; Mikhail S Novikov; Vladimir T Valuev-Elliston; Sergey P Korolev; Anastasia L Khandazhinskaya; Sergey N Kochetkov; Suresh Gupta; Julian Goding; Elijah Bolotin; Marina B Gottikh; Alexei A Bogdanov
Journal:  Nanomedicine       Date:  2016-07-25       Impact factor: 5.307

6.  Tailoring Lipid and Polymeric Nanoparticles as siRNA Carriers towards the Blood-Brain Barrier - from Targeting to Safe Administration.

Authors:  Maria João Gomes; Carlos Fernandes; Susana Martins; Fernanda Borges; Bruno Sarmento
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-21       Impact factor: 4.147

Review 7.  Nanoparticle-based drug delivery to the vagina: a review.

Authors:  Laura M Ensign; Richard Cone; Justin Hanes
Journal:  J Control Release       Date:  2014-05-14       Impact factor: 9.776

Review 8.  Anti-HIV-1 nanotherapeutics: promises and challenges for the future.

Authors:  Supriya D Mahajan; Ravikumar Aalinkeel; Wing-Cheung Law; Jessica L Reynolds; Bindukumar B Nair; Donald E Sykes; Ken-Tye Yong; Indrajit Roy; Paras N Prasad; Stanley A Schwartz
Journal:  Int J Nanomedicine       Date:  2012-10-05

Review 9.  Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.

Authors:  Antoinette G Nelson; Xiaoping Zhang; Usha Ganapathi; Zoltan Szekely; Charles W Flexner; Andrew Owen; Patrick J Sinko
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 10.  Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.

Authors:  Edwin Coleridge S Naidu; Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Carmen Olivia Rennie; Onyemaechi Okpara Azu
Journal:  Pharmacol Res Perspect       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.